{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Robert", "organization": "", "rank": 1, "lastname": "CYRAN"}], "original": "By ROBERT CYRAN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "The Flaws in Pfizer\u2019s Plan to Acquire Medivation"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Pfizer Inc", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Medivation Inc", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Astellas Pharma", "is_major": "N", "rank": "5", "name": "organizations"}], "snippet": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying....", "source": "The New York Times", "lead_paragraph": "A heated auction and back-of-the-envelope math hint that the buyer is overpaying.", "word_count": "376", "pub_date": "2016-08-23T04:00:00+0000", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/08/23/business/dealbook/the-flaws-in-pfizers-plan-to-acquire-medivation.html", "_id": "57bb5b0295d0e021d798203d"}